Skip to main content
. 2018 Dec 14;42(2):281–287. doi: 10.2337/dc18-1512

Table 1.

Clinical characteristics of the study group participants

Overall Control subjects AAB FDR AAB+ single AAB+ multiple Recent onset
N (%) 229 49 (21.4) 61 (26.6) 31 (13.5) 36 (15.7) 52 (22.7)
Male sex 101 (44.1) 20 (40.8) 23 (37.7) 9 (29.0) 22 (61.1) 27 (51.9)
Age (years) 19.6 ± 10.5 18.4 ± 5.9 21.1 ± 11.7 28.8 ± 13.3 15.9 ± 10.7 16.2 ± 6.1
Body weight (kg) 61.0 ± 23.7 61.8 ± 17.8 63.0 ± 22.1 75.3 ± 31.0 49.9 ± 22.6 61.3 ± 23.0
BMI 23.2 ± 6.4 22.7 ± 4.8 23.6 ± 6.1 27.6 ± 8.6 20.0 ± 5.7 22.6 ± 5.9
PV 74.9 ± 31.8 88.2 ± 30.8 81.2 ± 29.8 89.3 ± 35.4 61.2 ± 28.0 55.7 ± 21.6
RPVBW 1.2 ± 0.4 1.4 ± 0.4 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.2 0.9 ± 0.2
RPVBMI 3.2 ± 1.1 3.9 ± 1.1 3.5 ± 0.9 3.3 ± 1.1 3.0 ± 1.0 2.5 ± 0.2
RPV-to-height ratio 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.1 0.3 ± 0.1
Race/ethnicity
 NH white 177 (77.3) 28 (57.1) 52 (85.3) 25 (80.7) 29 (80.6) 43 (82.7)
 NH black 11 (4.8) 5 (10.2) 1 (3.2) 3 (8.3) 2 (3.9)
 NH Asian 2 (0.9) 1 (2.0) 1 (1.9)
 NH Am. Indian, Alaska Native
 NH Hawaiian, Pacific Islander 1 (0.4) 1 (2.0)
 Hispanic 27 (11.8) 6 (12.2) 8 (13.1) 4 (12.9) 4 (11.1) 5 (9.6)
 NH multiple race/unknown 11 (4.8) 8 (16.3) 1 (1.6) 1 (3.2) 1 (1.9)
Laboratory tests*
 HbA1c (%) 5.5 ± 1.0 5.0 ± 0.3 5.1 ± 0.3 5.2 ± 0.3 5.1 ± 0.4 7.0 ± 1.3
 HbA1c (mmol/mol) 36.8 ± 11.2 31.5 ± 3.6 32.0 ± 3.3 33.5 ± 3.5 32.6 ± 3.9 52.6 ± 13.9
 Glucose (mg/dL) 104.0 ± 37.5 90.0 ± 6.0 93.0 ± 6.7 96.0 ± 8.7 94.7 ± 16.0 141.4 ± 64.3
 C-peptide (ng/mL) 2.0 ± 1.2 2.1 ± 0.7 2.3 ± 1.3 2.5 ± 1.2 1.9 ± 1.2 1.2 ± 0.9
 Trypsinogen (ng/mL) 23.9 ± 18.9 23.4 ± 10.0 25.8 ± 12.4 38.2 ± 40.5 20.0 ± 8.6 16.3 ± 9.9

Data are mean ± SD or N (%). Am. Indian, American Indian; NH, non-Hispanic.

*HbA1c (% and mmol/mol), n missing = 5; glucose, n missing = 0; C-peptide, n missing = 1; trypsinogen, exclusion of outlier n = 1 and missing for analysis = 16.